Dipeptidyl peptidase 4 (DPP4), also known as CD26, is a multifunctional enzyme widely recognized for its critical role in glucose metabolism through the degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). Assay kits designed to measure DPP4 activity provide a valuable tool for studying its enzymatic function and involvement in various metabolic processes beyond glucose regulation.
DPP4 in Metabolic Regulation Beyond Glucose Homeostasis
While DPP4's role in glucose metabolism is well-established, recent research reveals its involvement in broader metabolic pathways, including lipid metabolism, insulin resistance, inflammation, and adipose tissue function.
DPP4 as an Adipokine and Its Role in Adipose Tissue
DPP4 is expressed and secreted by adipocytes, particularly mature adipocytes in visceral fat, acting as an adipokine with autocrine and paracrine effects. Its expression increases during adipocyte differentiation, and it is implicated in modulating adipose tissue metabolism and insulin signaling.
In human white adipocytes, DPP4 knockdown alters gene expression significantly, increasing metabolic genes like PDK4 and PPARγC1α, which are involved in energy metabolism and mitochondrial biogenesis, while decreasing proliferation-related genes. This suggests that DPP4 influences adipocyte differentiation and function, potentially linking it to obesity and metabolic syndrome.
Influence on Insulin Resistance and Inflammation
DPP4 can impair insulin signaling in adipocytes and other tissues, contributing to insulin resistance. Studies show that exogenous DPP4 reduces insulin receptor signaling pathways, including Akt phosphorylation, while silencing DPP4 improves insulin responsiveness. These effects may involve both enzymatic activity and non-catalytic interactions, such as binding to extracellular matrix components and caveolin-1, which modulate cellular signaling.
Moreover, DPP4 promotes a proinflammatory environment in adipose tissue, which is a key factor in the development of metabolic diseases like type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).
Regulation by Glucose and Pathological Conditions
Under physiological conditions, glucose negatively regulates DPP4 expression in adipocytes, but this regulation is lost in diabetic or insulin-resistant states. For example, in high-fat diet or streptozotocin-induced diabetic mice models, adipocyte DPP4 levels are elevated despite high glucose concentrations, suggesting dysregulation of DPP4 contributes to metabolic dysfunction.
Clinical and Therapeutic Implications
DPP4 inhibitors (gliptins) are used clinically to improve glucose control in T2DM by preventing incretin degradation. However, the broader metabolic roles of DPP4 suggest potential implications for obesity, insulin resistance, and inflammatory metabolic diseases. Elevated circulating DPP4 levels correlate with adipose tissue dysfunction and metabolic syndrome, highlighting DPP4 as a biomarker and therapeutic target beyond glucose metabolism.
DPP4 assay kits enable detailed study of DPP4 enzymatic activity, which is central not only to glucose metabolism but also to complex metabolic networks involving adipose tissue function, insulin resistance, and inflammation. Understanding these multifaceted roles of DPP4 can advance therapeutic strategies for metabolic diseases and provide insights into the pathophysiology of obesity-related disorders.
